# NeuroGuard: Psilocybin Trial for Preventing Chemo-induced Neuropathy

> **NCT07227909** · PHASE2 · NOT_YET_RECRUITING · sponsor: **M.D. Anderson Cancer Center** · enrollment: 83 (estimated)

## Conditions studied

- Psilocybin
- Neuropathy

## Interventions

- **DRUG:** Psilocybin (drug)
- **DRUG:** Psilocybin (drug)
- **OTHER:** Standard of Care (SOC)

## Key facts

- **NCT ID:** NCT07227909
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-05-04
- **Primary completion:** 2029-01-31
- **Final completion:** 2031-01-31
- **Target enrollment:** 83 (ESTIMATED)
- **Last updated:** 2026-04-16

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07227909

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07227909, "NeuroGuard: Psilocybin Trial for Preventing Chemo-induced Neuropathy". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT07227909. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*